S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News

$0.32
+0.04 (+14.29%)
(As of 03/30/2023 04:00 PM ET)
Add
Compare
Today's Range
$0.28
$0.33
50-Day Range
N/A
52-Week Range
$0.16
$1.24
Volume
258,078 shs
Average Volume
147,005 shs
Market Capitalization
$10.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NAVB stock logo

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Stock News Headlines

Q4 2022 Navidea Biopharmaceuticals Inc Earnings Call
Biden’s Big Lie…
Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. pixel
NAVB.PH - | Stock Price & Latest News | Reuters
Biden’s Big Lie…
Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. pixel
Navidea Biopharmaceuticals Files Appeal in CRG Case
Navidea Biopharmaceuticals, Inc. (NAVB)
See More Headlines
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Company Calendar

Last Earnings
11/10/2021
Today
3/30/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSEAMERICAN:NAVB
Previous Symbol
NYSEMKT:NAVB
CUSIP
63937X10
Employees
11
Year Founded
N/A

Profitability

Net Income
$-11,730,000.00
Pretax Margin
-13,229.31%

Debt

Sales & Book Value

Annual Sales
$530,000.00
Book Value
$0.02 per share

Miscellaneous

Free Float
17,619,000
Market Cap
$10.29 million
Optionable
Optionable
Beta
1.36

Key Executives

  • Michael S. Rosol
    Senior VP, Chief Executive & Medical Officer
  • Jeffrey G. Smith
    Vice President-Operations
  • Erika L. Eves
    Vice President-Finance & Administration
  • Richard McFerron
    Director-Regulatory Affairs













NAVB Stock - Frequently Asked Questions

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 438,500 shares, an increase of 38.2% from the January 31st total of 317,300 shares. Based on an average daily trading volume, of 150,900 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.1% of the shares of the company are short sold.
View Navidea Biopharmaceuticals' Short Interest
.

When is Navidea Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our NAVB earnings forecast
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John K Jr Scott and Malcolm G Witter.
View institutional ownership trends
.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.32.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $10.29 million and generates $530,000.00 in revenue each year. The biopharmaceutical company earns $-11,730,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for the company is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522.

This page (NYSEAMERICAN:NAVB) was last updated on 3/30/2023 by MarketBeat.com Staff